LADENBURG THALMANN FINANCIAL SERVICES INC. - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 103 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2018. The put-call ratio across all filers is 0.50 and the average weighting 0.1%.

Quarter-by-quarter ownership
LADENBURG THALMANN FINANCIAL SERVICES INC. ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q4 2019$88,000
+17.3%
25,673
-1.9%
0.00%0.0%
Q3 2019$75,000
+2400.0%
26,173
+4101.1%
0.00%
Q2 2019$3,000
-25.0%
623
+27.4%
0.00%
Q1 2019$4,000
+33.3%
489
+25.7%
0.00%
Q4 2018$3,000
-25.0%
389
-20.4%
0.00%
Q3 2018$4,000
+100.0%
489
+25.7%
0.00%
Q2 2018$2,0000.0%3890.0%0.00%
Q1 2018$2,0000.0%3890.0%0.00%
Q4 2017$2,0000.0%3890.0%0.00%
Q3 2017$2,0000.0%3890.0%0.00%
Q2 2017$2,000
-33.3%
3890.0%0.00%
Q1 2017$3,000
+50.0%
3890.0%0.00%
Q4 2016$2,0000.0%3890.0%0.00%
Q3 2016$2,000
-96.6%
389
-98.1%
0.00%
-100.0%
Q2 2016$58,000
+100.0%
20,389
+96.3%
0.00%0.0%
Q1 2016$29,000
+625.0%
10,389
+2570.7%
0.00%
Q4 2015$4,0000.0%3890.0%0.00%
Q3 2015$4,000
-96.4%
389
-94.7%
0.00%
-100.0%
Q2 2015$110,000
+214.3%
7,389
+90.0%
0.00%
+100.0%
Q1 2015$35,000
-18.6%
3,889
+11.1%
0.00%0.0%
Q4 2014$43,000
+48.3%
3,500
+16.7%
0.00%0.0%
Q3 2014$29,000
-23.7%
3,0000.0%0.00%0.0%
Q2 2014$38,000
+375.0%
3,000
+200.0%
0.00%
Q4 2013$8,000
+14.3%
1,0000.0%0.00%
Q3 2013$7,000
-83.7%
1,000
-96.4%
0.00%
-100.0%
Q2 2013$43,00028,0000.00%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q1 2018
NameSharesValueWeighting ↓
DG Capital Management, LLC 1,186,726$4,076,0002.45%
Sarissa Capital Management LP 4,861,000$16,697,0001.97%
Ghost Tree Capital, LLC 1,950,000$6,698,0001.94%
ORACLE INVESTMENT MANAGEMENT INC 2,525,857$8,676,0001.14%
Eversept Partners, LP 1,143,211$3,926,9300.87%
DAFNA Capital Management LLC 749,051$2,573,0000.84%
KNOTT DAVID M 397,361$1,365,0000.80%
Parkman Healthcare Partners LLC 800,740$2,751,0000.73%
ACUTA CAPITAL PARTNERS, LLC 660,000$2,267,0000.62%
Formidable Asset Management, LLC 578,200$1,949,0000.57%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders